Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Orexigen Struggles as Contrave Commercialization Costs Rise

Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

    5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now

    Let's take a look at few factors that help in determining if Novo Nordisk (NVO) will be a good investment in 2018.

      The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

      The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S

        4 Large-Cap Pharma Stocks That Outperformed the S&P This Year

        We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.

          Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion

          Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.

            Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

            Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

              Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes

              Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.

                Sanofi's Toujeo Meets Key Objective in Head-to-Head Study

                Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes

                  Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.

                    Arpita Dutt headshot

                    5 Biotech and Pharma Stocks with FDA Catalysts this December

                    As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.

                      2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17

                      Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.

                        Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

                        Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

                          The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel

                          The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel

                            J&J Presents Positive New Data for Diabetes Drug Invokana

                            Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.

                              Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales

                              Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.

                                Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up

                                Alexion Pharmaceuticals, Inc.???s (ALXN) beat earnings estimates but missed sales estimates in the third quarter of 2017.

                                  United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat

                                  United Therapeutics' (UTHR) earnings grow year over year in the third quarter of 2017. Revenues too surpass estimates in the reported quarter.

                                    Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss

                                    The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.

                                      Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics

                                      AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.

                                        Impax Laboratories and Amneal Pharmaceuticals Agree to Merge

                                        Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.

                                          Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

                                          Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

                                            Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

                                            Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

                                              Immune Design's Sarcoma Candidate to Enter Phase III in 2018

                                              Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.

                                                Bristol-Myers Gets Priority Review for Opdivo Label Expansion

                                                Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

                                                  Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

                                                  GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.